How Ipamorelin Affects Fasting Insulin and HOMA-IR

Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R1a) agonist that triggers discrete GH pulses from pituitary somatotrophs. Its insulin-sensitivity profile is defined by what it does not do as much as what it does:

1. Pulsatile GH: intermittent rather than sustained insulin resistance: Each ipamorelin injection produces a GH pulse peaking at approximately 40 minutes and resolving within 2 to 3 hours (Gobburu et al., 1999). GH raises insulin resistance acutely by promoting lipolysis and FFA release and by suppressing IRS-1 phosphorylation in skeletal muscle. With full baseline GH levels restored between pulses, insulin sensitivity normalises. Fasting insulin, measured in the morning before any injection, reflects this inter-pulse normalised state.
2. No ghrelin-receptor pancreatic action: Ghrelin activates GHS-R1a receptors in both the pituitary and the pancreas. Pancreatic GHS-R1a activation suppresses insulin secretion from beta cells (Dezaki et al., 2004), which reduces insulin availability and secondarily impairs glucose disposal. Ipamorelin activates GHS-R1a selectively in the pituitary with minimal off-target receptor activity, meaning it does not directly suppress pancreatic insulin output.
3. No appetite-driven hyperinsulinemia: MK-677 raises appetite through ghrelin receptor activation in the hypothalamus, promoting caloric intake and subsequent postprandial insulin spikes. Ipamorelin's pituitary selectivity means no appetite amplification, no additional caloric load, and no secondary hyperinsulinemia.
4. Selectivity confirmed by Raun et al. (1998, PMID 9849822): The pivotal ipamorelin selectivity paper demonstrated GH release without significant changes in ACTH, cortisol, prolactin, or pancreatic hormones (including insulin) at doses up to 200 times the effective GH-releasing dose. This establishes the hormonal selectivity that is ipamorelin's defining pharmacological characteristic.

Standard ipamorelin protocol (200-300 mcg SC, 1-2 times daily):

• Fasting insulin: no clinically significant change expected
• HOMA-IR: no clinically significant change expected
• Fasting glucose: no clinically significant change (see ipamorelin-glucose entry)

Combined CJC-1295 no-DAC plus ipamorelin protocol:

• GH pulse amplitude increases; the larger pulse may produce a slightly greater acute post-injection insulin and glucose transient
• Fasting measurements (taken before the first injection of the day) remain essentially unchanged

Comparison with MK-677 (25 mg/day, 2-year RCT, Nass et al. 2008):

• MK-677 raised fasting glucose 0.3 mmol/L, raised HbA1c 0.2%, and elevated fasting insulin with compensatory hyperinsulinemia
• Ipamorelin at standard doses produces a fraction of this metabolic load, consistent with the pulsatile mechanism

Baseline: Fasting glucose and fasting insulin before starting. Calculate HOMA-IR as a reference.

During use:

• Fasting glucose and insulin every 6 months on a long-term ipamorelin protocol
• Increase to quarterly if stacking with MK-677, exogenous GH, or AAS
• Recheck fasting insulin 8 to 12 weeks after starting if baseline HOMA-IR is borderline (above 1.5)

Timing of blood draw: Collect fasting insulin at least 4 hours after the most recent ipamorelin injection to avoid the acute post-injection insulin surge from the GH pulse. Morning fasting draws before the first daily injection are ideal.

If baseline insulin resistance is present:

• Ipamorelin is the most metabolically conservative GH secretagogue choice for users with pre-diabetes, central obesity, or family history of type 2 diabetes
• Consider once-daily dosing rather than twice-daily to minimise total daily GH pulse burden
• Pair with resistance training and aerobic exercise, which independently improve insulin sensitivity

If HOMA-IR rises above 2.0 on ipamorelin:

• First investigate independent drivers: dietary changes, body fat gain, sleep disruption, AAS co-use, other new compounds
• If ipamorelin appears to be the driver, reduce to once-daily dosing
• Berberine 500 mg twice daily with meals is a reasonable adjunct

Transitioning users off MK-677:

• Users switching from MK-677 to ipamorelin commonly see fasting insulin and HOMA-IR normalise within 4 to 8 weeks
• Ipamorelin can maintain a portion of the IGF-1 benefit (typically 15 to 40% above baseline vs MK-677's 50 to 100%) with substantially better metabolic outcomes
• Adding CJC-1295 no-DAC to ipamorelin amplifies IGF-1 response while maintaining the metabolic advantage